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Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory condition char-
acterized by oxidative stress and the formation of volatile organic compounds (VOCs) secreted
via the lungs. We recently developed a methodological approach able to identify profiles of
VOCs in breath unique for patient groups. Here we applied this recently developed method-
ology regarding diagnosis of COPD patients.
Methods: Fifty COPD patients and 29 controls provided their breath and VOCs were analyzed
by gas chromatographyemass spectrometry to identify relevant VOCs. An additional 16 COPD
patients and 16 controls were sampled in order to validate the model, and 15 steroid naı¨ve
COPD patients were sampled to determine whether steroid use affects performance.
Findings: 1179 different VOCs were detected, of which 13 were sufficient to correctly classify
all 79 subjects. Six of these 13 VOCs classified 92% of the subjects correctly (sensitivity: 98%,
specificity: 88%) and correctly classified 29 of 32 subjects (sensitivity: 100%, specificity: 81%)
from the independent validation population. Fourteen out of 15 steroid naı¨ve COPD patients
were correctly classified thus excluding treatment influences.
Interpretation: This is the first study distinguishing COPD subjects from controls solely based
on the presence of VOCs in breath. Analysis of VOCs might be highly relevant for diagnosis
of COPD.
ª 2009 Elsevier Ltd. All rights reserved.AT.unimaas.nl (F.J. Van Schooten).
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In the last few decades the mortality of chronic obstructive
pulmonary disease (COPD) has increased worldwide, even in
industrialized countries. The main feature of COPD is irre-
versible airflow limitation as a result of emphysematous
destruction, increasing both compliance of the lung and the
resistance of the small airways. COPD is a leading cause of
mortality and morbidity, and estimates from the World
Health Organization state that in 2001 COPD was the fifth
leading cause of death in high-income countries and the
sixth leading cause of death in low and middle income
countries.1 Early diagnosis and treatment will be necessary
in order to control its high morbidity and mortality and
consequently high healthcare cost.2 Spirometry is currently
the gold standard for diagnosing and monitoring progression
of COPD. However, in order to ensure quality, the practice
nurse has to be trained on how to perform spirometry and
general practitioners on how to evaluate spirograms. Only
under these prerequisites, office spirometry can help iden-
tify the presence of asthma and COPD if breathing symptoms
are present. In the early stage of COPD, breathing symptoms
might not be clinically manifest. Especially identification of
these early stages of COPD by using VOC analysis in exhaled
air might prove clinically relevant. Our proposed method-
ology indeed detected inflammation related compounds in
exhaled air, in contrast to early detection of COPD with the
current gold standard, spirometry.
A relatively new concept, the analysis of exhaled air,
might provide more accurate diagnosis and might prove
useful as a new non-invasive, safe and fast diagnostic tool
regarding the diagnosis of inflammatory lung diseases,
including asthma, cystic fibrosis and COPD. Regarding the
analysis of exhaled air several biomarkers for several
diseases have already been identified. Nitric oxide (NO)
levels are generally accepted as an indication of inflam-
mation and oxidative stress in the respiratory tract in for
instance asthma.3 However, in COPD the use of NO is
limited since exhaled NO levels are not or only marginally
elevated in COPD patients.4 Additionally carbon
monoxide (CO) has been investigated as a COPD
biomarker, and likewise with NO, contrasting results are
published. Yamaya et al. found a significant relationship
between exhaled CO concentrations and FEV1, and
exhaled CO appeared to correlate with the eosinophil
count in sputum.5 Others found no correlation of exhaled
CO with lung function.6 The application of CO as a diag-
nostic marker is also limited because exhaled CO levels
are affected by environmental CO, which may fluctuateTable 1 Study subject characteristics.
Study population Training set
Controls (nZ 29) COPD (nZ
Age, yr (mean SD) 50 9 71 8
Sex, M/F 14/15 38/12
FEV1, % predicted (mean SD) 90 14 50 15
RV, % predicted (mean SD) 77 19 176 34
Smoking status, current/ex/non 9/7/13 38/6/6
Pack-years (mean SD) 18 7 49 12considerably and is influenced by active and passive
smoking, making its use as a biomarker for COPD at the
least questionable.7
Additionally exhaled volatile compounds have been
studied regarding their hypothesized function as biomarkers
of oxidative stress for example ethane. Ethane belongs to
the group of volatile organic compounds (VOCs) and is
demonstrated to be elevated in exhaled air of COPD patients
compared to controls. A correlation was also demonstrated
between levels of ethane and the degree of airway
obstruction, smoking habits and FEV1.
8 However, the anal-
ysis of single compounds from exhaled air is hampered by
low sensitivity and specificity. In 1971 Pauling et al. already
demonstrated the availability of hundreds of different VOCs
in exhaled air9 and many more have been identified since.
Philips et al. have recently successfully demonstrated the
possibility of using a profile of VOCs in breath as biomarkers
of lung cancer and pulmonary tuberculosis.10e12 Therefore
we are particularly interested in multicomponent analysis of
VOCs in COPD patients in order to increase performance
using a biomarker profile approach. This approach may have
great potential regarding clinical application for the
assessment of airway inflammation. Especially, analysis of
exhaled air provides a fast, non-invasive, cost beneficial and
easy to perform diagnostic tool.
The aim of this study was to identify COPD biomarkers
from exhaled air able to discriminate patients suffering
from COPD from non-diseased controls. We investigated
VOCs in exhaled air from COPD patients and controls by
means of a recently developed approach13 and identified
profiles that were able to identify the diseased state.Materials and methods
Study subjects
As a training population a total of 50 COPD patients and 29
non-diseased controls both smoking and non-smoking were
recruited at Maastricht University, the Netherlands. Subject
characteristics are shown in Table 1. Diagnosis of COPD was
based on examination of pulmonary function according to
international GOLD guidelines by experienced medical
staff. Subjects were sampled at centrally ventilated
treatment rooms located in the hospital. Non-diseased
control subjects were staff members. A medical interview
and subjects’ medical history confirmed absence of respi-
ratory disease in these subjects, as additionally confirmed
by spirometry results.Validation set Steroid naive
50) Controls (nZ 16) COPD (nZ 16) COPD (nZ 15)
51 6 63 6 57 8
8/8 11/5 8/7
92 7 53 13 57 12
72 13 154 29 148 13
3/3/10 2/14/0 3/9/3
12 5 35 6 29 26
VOC form breath discriminate COPD from controls 559Another set of 16 COPD patients and 16 non-diseased
controls were obtained from the Centre for Integrated
Rehabilitation Organ Failure (CIRO). This population was
used as a validation population to validate the results that
were obtained in the training population. Additionally, a set
of 15 subjects was sampled at the University Hospital
Maastricht diagnosed as COPD patients, and exhaled air was
obtained before therapeutic treatment with steroids was
initiated. All subjects gave their informed consent and the
study protocol was approved by the medical ethics
committee of Maastricht University.
Sample collection and analysis
Participants were asked to inhale, hold their breath for 5 s
and subsequently fully expire into resistance free tedlar
bags (5 L). The content of the bag was transported under
standardized conditions onto stainless steel two-bed sorp-
tion tubes, filled with carbograph 1TD/Carbopack X (Markes
International, Llantrisant, Wales, UK) that trap VOCs. These
sorption tubes were placed inside a thermal desorption unit
(Marks Unity desorption unit, Markes International Limited,
Llantrisant, Wales, UK) and subsequently heated to 270 C
in order to release all VOCs onto the gas chromatography
capillary column (RTX-5ms, 30 m 0.25 mm 5% diphenyl,
95% dimethylsiloxane capillary, film thickness 1 mm). VOCs
are separated by GC (ThermoFisher Scientific., Austin,
Texas, USA) and subsequently detected by a time-of-flight
mass spectrometer (TOF-MS) (Thermo Electron Tempus Plus
time-of-flight mass spectrometer, ThermoFisher Scientific,
Austin, Texas, USA). The temperature of the gas chro-
matograph was programmed as follows: 40 C during 5 min,
then raised with 10 C/min until the final temperature of
270 C, this temperature was maintained for 5 min. Elec-
tron ionisation mode at 70 eV was used with a 5 Hz scanning
rate over a mass range of m/z 35e350 amu. An example
breathogram is shown in Fig. 1.
Data-acquisition and mining
Analysis of the data output files from the GCeTOF-MS was
performed in successive steps as previously described in
detail.13 In summary the first step was to perform peak
detection and baseline corrections on all analysis output0 5 10 15
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Figure 1 Example of a breathogram as measured by gafiles. Normalization of the calculated peak areas was per-
formed using an area-scaling factor. This rescaling factor
used is based on the cumulative area under the detected
peaks, since all chromatograms display rather similar
profiles this method of normalization is most robust.
Next retention times (RTs) of all subjects were corrected
for chromatographic drifting and lined up. Applying this
correction for retention times is very effective and easy to
perform eliminating the use of an added internal standard,
adding to the straight-forwardness and easy to perform
routine of the presented methodology.
Finally, the output files were merged by combining
corresponding compounds based on degree of similarity of
the corresponding mass spectra e by determining the
match factor values (MFs) e and similarity of RT. The
degree of mass spectra similarity was calculated using
a match factor based on the similarity index as described by
Stein et al.14 These match factors were only determined for
compounds within a selectable RT-window.
Component selection
To determine which compounds in the database were of
interest regarding the classification of diseased versus
controls, we applied support vector machines (SVMs).
Support vector machines demonstrate the ability to
construct predictive models with large generalization
power even in the case of large dimensionality of the data
or when the number of observations available for training is
low. SVM always seeks a globally optimized solution and
avoid over-fitting. This implies that a large number of
features (i.e. compounds) are allowed.15 This encouraged
us to implement this subset selection algorithm into this
study, since it will select the most optimal subset of
compounds able to correctly classify our dataset. A variety
of selection methods were tested using the software
program ‘Weka’: a collection of machine learning algo-
rithms for data mining tasks. Compounds were selected
using an SVM attribute evaluator. The attribute evaluator
we used evaluates the worth of a subset of attributes by
considering the individual predictive ability of each feature
along with the redundancy between them. Preferably
features will be selected showing high correlations within
the class and low intercorrelation. Next, the selected20 25 30
inutes)
s chromatography time-of-flight mass spectrometry.
560 J.J.B.N. Van Berkel et al.compounds were analyzed and ranked with use of SVM using
recursive feature selection and removing one attribute at
a time. This way attributes were selected using the weight
magnitude as ranking criterion. After every run the least
efficient attribute was removed. All resulting subsets were
analyzed for classification performance with use of support
vector classifiers based on John Platt’s sequential minimal
optimization algorithm and the random forest classification
algorithm.16
Results
Discriminating VOCs as subtracted from training
dataset
The resulting analysis of exhaled air demonstrated that the
exhaled air is rich in a wide variety of VOCs. A total of 3778
different compounds were found and a mean of 332
different VOCs were detected per subject. The final COPD
dataset consisted of 50 COPD patients and 29 non-diseased
subjects. Compounds detected in less than 8% of subjects
were discarded resulting in a dataset of 79 subjects and
1179 compounds using a match factor-threshold of 0.85 and
an RT-window of 12 s. Used MF-threshold values were
determined based on a variety of complementary
compounds manually combined. The MFs calculated for
these compounds demonstrated to be at least 0.852. The
RT-window value was chosen based on analysis of the
maximum RI-range of complementary compounds found in
several subject files.
As shown in Table 2, a classification model was con-
structed based on 13 VOCs. This model is able to classify
both controls and COPD patients 100% correctly, tested
with 10 times cross-validation. Classification performance
of SVM based on more than 13 VOCs performed equal to the
SVM based on this minimal amount of 13 VOCs. These 13Table 2 Classification performance tested with 10 times cross-v
patients, 29 controls). A support vector classifier was used train
Correct classification was achieved with use of 13 VOCs from ex
cumulative contribution and performance is evaluated in a cumula
validation set consisting of 32 subjects (16 COPD patients, 16 c
compounds implemented into the optimal classification algorithm
retention time (RT) for every compound.
Chemical structure RT (min) Training se
Sens.
Isoprene* 2.6 0.96
C16 hydrocarbon* 23.3 0.96
4,7-Dimethyl-undecane* 19.5 0.96
2,6-Dimethyl-heptane* 10.5 0.98
4-Methyl-octane* 11.3 0.98
Hexadecane* 23.2 0.98
3,7-Dimethyl 1,3,6-octatriene 14.5 1.00
2,4,6-Trimethyl-decane 19.5 1.00
Hexanal 9.9 1.00
Benzonitrile 14.1 1.00
Octadecane 25.5 1.00
Undecane 16 1.00
Terpineol 14.9 1.00VOCs were identified as: isoprene, C16 hydrocarbon,
4,7-dimethyl-undecane, 2,6-dimethyl-heptane, 4-methyl-
octane, hexadecane, 3,7-dimethyl, 1,3,6-octatriene, 2,4,6-
trimethyl-decane, hexanal, benzonitrile, octadecane,
undecane, terpineol. For one compound it was not possible
to identify the compound with certainty only that it con-
sisted of a hydrocarbon containing a 16-carbon chain. Fig. 2
shows the component mean area under peak and avail-
ability of the compounds.
Evaluation performance of discriminating VOCs in
validation datasets
The performance of the generated SVM classifier based on
the 13 VOCs as shown in Table 2 was evaluated on the
validation population, consisting of 16 COPD patients and
16 controls. The COPD patients and controls used as vali-
dation population were sampled at separate locations and
another period of time compared to the training
population.
The results of testing the 13 VOCs on the validation set
show that misclassifications occur due to over-fitting of the
data leading to lower levels of specificities (Table 2). This
means that the classification model based on the 13 VOCs is
too specific towards the COPD training dataset and lacks
performance when tested on the independent validation
dataset. The logical step was to lower the number of VOCs
implemented into the classification algorithm thus reducing
misclassifications. As shown in Table 2, a classifier trained
on the COPD training set containing 6 VOCs performed best
on the validation set. Therefore the preferred classification
model is based on 6 VOCs and these are indicated by an
asterisk in Table 2.
The support vector classifier built from the COPD
training set based on these 6 VOCs demonstrated an
optimum of 91% correct classification as tested on the 32alidation on COPD dataset consisting of 79 subjects (50 COPD
ed by the sequential minimal optimization algorithm (SMO).
haled air. The displayed VOCs are ranked according to their
tive manner. VOC profiles were also tested on an independent
ontrols), and on steroid naı¨ve COPD patients (nZ 15). The
are denoted by an asterisk. The second column shows the
t Validation set Steroid naive
Spec. Sens. Spec. Sens.
0.41 1.00 0.56 0.46
0.55 1.00 0.75 0.60
0.69 1.00 0.75 0.60
0.69 1.00 0.50 0.80
0.76 1.00 0.69 0.87
0.83 1.00 0.82 0.93
0.83 1.00 0.56 0.87
0.90 0.94 0.69 0.87
0.90 0.94 0.69 0.87
0.93 0.94 0.69 0.93
0.90 0.94 0.69 0.93
0.90 1.00 0.63 0.93
1.00 1.00 0.75 0.93
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Figure 2 Relative amounts of compounds used in the classification algorithm. Each bar represents mean and standard error
values for one compound detected in either control subjects or COPD patients. The height of every bar denotes the mean and
standard errors are denoted by the error bars. Grey bars represent patients suffering from COPD, black bars represent control
subject data. (a) Isoprene, (b) C16 hydrocarbon, (c) 4,7-dimethyl-undecane, (d) 2,6-dimethyl-heptane, (e) 4-methyl-octane, (f)
hexadecane, (g) 3,7-dimethyl 1,3,6-octatriene, (h) 2,4,6-trimethyl-decane, (i) hexanal, (j) benzonitrile, (k) octadecane, (l)
undecane, and (m) terpineol. The numbers over the error bars denote the availability and the percentage of subjects in which the
compound was detected.
VOC form breath discriminate COPD from controls 561subject validation set. This corresponds to a misclassifica-
tion of only 3 samples out of 32 demonstrating a specificity
of 81% and a sensitivity of 100%. So, all COPD patients were
correctly identified and only 3 healthy subjects were
incorrectly seen as COPD patients. This illustrates the
robustness of our approach that even when sampling is
done under different circumstances the discriminating
VOCs show similar levels of specificity and sensitivity in
both study populations.
In order to be sure that the 6 VOCs were not discrimi-
nating between controls and COPD patients because of the
use of medication by COPD patients, their performance was
tested on exhaled air samples obtained from 15 steroid
naı¨ve COPD patients. Fourteen out of these 15 subjects
suffering from COPD not using any medication were
correctly classified as COPD by our optimized 6 component
classifier demonstrating a sensitivity of 93%.Discussion
We have shown in the present paper that measuring
multiple VOCs in exhaled air offers an excellent possibility
as future diagnostics of COPD patients. In addition to the
good performance of the VOC profile in discriminating
diseased versus healthy subjects, sampling of exhaled air is
non-invasive, safe and does not cause any degree of
discomfort to the patients. We present a highly accurate
classification model based on 6 VOCs that is not confoundedby time of sampling, ambient air, use of medication and
former or current tobacco smoking. Using sophisticated
bioinformatics tools we extracted 6 VOCs out of nearly 1200
exhaled compounds that combined into an accurate SVM
model. This model proved to be highly sensitive and specific
in determining whether a person is diseased or healthy. The
implemented compounds appeared to be mainly long chain
hydrocarbons.
It was our aim to develop a robust diagnostic method-
ology that can be implemented in clinical daily practices
without encountering too many confounding obstacles. In
principal the excretion of VOCs can be influenced by many
factors of intrinsic nature (gender, age, weight, genetic
background) or of exogenous origin (ambient air, diet or
medication). It is practically impossible to control all these
potentially confounding factors. Therefore it was our goal
to select those compounds that provide information
regarding diseased versus healthy status, independently
from other endogenous or exogenous factors. We recently
published our sampling procedure, chemical analysis, data
handling and accurate data mining methodology13 and
extensively showed that the developed methodology is
highly reproducible. Since the performance of the 6
discriminating VOCs was similar in both training populations
sampled at different locations it is clear that ambient air is
not a major confounder. Furthermore, we studied whether
the use of medication can be considered as a confounder by
examining the performance of the 6 VOCs on COPD patients
who received no treatment. These persons were sampled
562 J.J.B.N. Van Berkel et al.immediately before the diagnosis by lung function and the
VOC profiles were again highly sensitive to diagnose the
COPD patients since they were all but one recognized as
diseased. However, as shown in Table 1 the steroid naı¨ve
validation group consisted of subjects mainly in GOLD
classes I and II, while the training group consisted of
subjects mainly in GOLD classes II and III. This was due to
the low availability of steroid naı¨ve COPD patients. None-
theless the SVM model based on 6 VOCs was able to
correctly classify 14 out of 15 COPD subjects.
As can be concluded from Table 1 controls and COPD
subjects are not optimally matched regarding age. This
difference, however, does not demonstrate to be of great
importance since the degree of overlap between controls
and COPD in the training set with regards to age is large but
due to a few very old COPD patients included age seems to
be poorly matched. According to the results from the vali-
dation set and steroid naı¨ve set e where subjects are far
better matched for age e we can clearly state that the
selected compounds do relate to disease status instead of
age or smoking behavior.
In the field of exhaled air analyses, there is an ongoing
discussion whether or not background measurements
should be taken into account in order to correct for
ambient air influences. In the present work, no background
correction was applied to keep the methodology as easy
and straightforward as possible. Moreover, Miekisch et al.
mentioned that it will not be possible to correct for the
complex interdependencies between excretion and uptake
of VOCs by easily subtracting the peak areas obtained from
inhaled and exhaled air.17 Additionally background noise is
expected to be randomly distributed between subjects’
samples if sampled randomly and would thus not exert any
discriminatory power, nor interfere with the outcome of
the analyses.
Another point of discussion is the difference between
sampling alveolar and dead space air. Our sampling
approach samples a mixture of alveolar air and dead space
air, which is about 150 ml during tidal breathing. Partici-
pants were asked to inhale, hold their breath for 5 s and
subsequently fully expire. Since most of the subjects were
able to fully inflate the Tedlar bag in 2e4 expirations the
contribution of dead space air to the total volume is indeed
significant but nonetheless most of the obtained volume
originates from alveolar air. From this mixture one can
argue that alveolar air while diluted with dead space air
might result in sensitivity problems. However, in our anal-
ysis no sensitivity problems occurred. Although there are
sampling methods available of preventing dead space air
sampling, we decided not to use these methods to maintain
the ease of sampling. Furthermore, during previous studies
we explored the effect of different exhalation patterns on
VOC profiles and found no differences in breathograms
between superficial exhalation and deep exhalation.13
One of the innovative steps of our approach compared to
other studies in this field is that we use the raw mass
spectra to find the matching compounds in all subjects
instead of searching for matching compounds based on
their chemical identification. The latter procedure can
introduce many mistakes that jeopardize the quality of
databases, which attenuates the discriminative power of
the analysis (garbage inegarbage out). We introduced thematch factor in our routine to determine the degree of
similarity between mass spectra. The main advantage is
that the mass spectra are compared with each other as
measured with the same instrumental setup instead of
comparison against mass spectra found in a library. The
experience is that most of the time low match factors are
found when measured mass spectra are compared to those
present in the library. Therefore a far superior database is
created when raw mass spectra are compared instead of
comparing compounds after improper identification.
The amounts in exhaled air of the compounds that per-
formed best in the classification model are predominantly
lower in COPD patients than in controls. An explanation for
this observation may be found in the complicated biological
equilibrium of formation and removal of VOCs in the human
body. The hypothesis is that the inflammation driven
oxidative stress is responsible for oxidizing macromole-
cules, including polyunsaturated fatty acids that are
abundantly present in membranes, leading to a series of
breakdown products excreted as VOCs. Thus, the relative
composition of VOCs in exhaled breath of COPD patients
can change as a result of the disease, and this change can
be either an increase or a decrease of certain compounds.
Indeed we observed a considerable number of compounds
that are significantly higher in COPD patients compared to
controls but these compounds are not implemented into
the optimized classification model due to their limited
discriminatory power. On the other hand a decline in
certain VOCs may occur since especially the longer chain
hydrocarbons are further oxidized into smaller compounds
due to enhanced oxidative stress and consequently their
amounts are decreased in exhaled air of COPD patients. It
appeared that the absence of a number of these long
chained VOCs is crucial for the diagnostic ability. Apart
from the oxidative stress hypothesis explaining changing
VOC composition in COPD patients, an alternative reason
may be that lungs are remodeled during COPD resulting in
altered gas exchange over the bloodelung barrier. Further
studies are necessary in clinical settings but also in
inflammation models to explain the biochemical origin, the
physiological meaning and exhalation kinetics of our
selected VOCs. Nevertheless without this mechanistic
knowledge the compounds may already be of value to base
a diagnostic tool for clinical settings.
Finally, we conclude that analysis of a profile of 6
identified VOCs in exhaled air provides an accurate, non-
invasive, easy to perform diagnostic tool in the diagnosis of
COPD patients. Recent developments on real time
measurements can bring early stage detection of COPD into
general practice in the near future.
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